Colorado State University, Flint Animal Cancer Center Applies Sensus Healthcare’s SRT Non-Surgical Treatment to Animal Care
Sensus Healthcare (Nasdaq: SRTS) announced a significant milestone as its SRT-100™ system successfully treated its first canine patient, Daisy, at Colorado State University's Flint Animal Cancer Center. Daisy had two mast cell tumors that were reduced after six treatments, avoiding surgery. This landmark event highlights Sensus's innovations in superficial radiation therapy (SRT), expanding the potential use of their technology in veterinary medicine. The partnership aims to develop treatment protocols and publish clinical data, promoting the commercial viability of SRT-100 in a new market.
- Successful treatment of the first canine patient using SRT-100, showcasing its effectiveness.
- Reduction in tumor size, eliminating the need for surgery.
- Partnership with CSU to develop treatment protocols and publish clinical data, enhancing credibility.
- Potential to expand into the veterinary market, creating new revenue streams.
- None.
Effectiveness and Utility of SRT-100™ Demonstrated in the Companion-Animal Market
Best-in-class localization features of SRT-100 enable new radiation therapy options in veterinary settings
BOCA RATON, Fla, March 16, 2021 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announced today that the first canine patient was successfully treated with the company’s SRT-100™ system. SRT-100 systems utilize Sensus Healthcare’s proprietary low-energy x-ray technology known as superficial radiation therapy (SRT) that enables radiation therapy to target harder-to-reach lesions, such as those often found in animal patients.
The canine, an American bulldog, named Daisy, was treated at Flint Animal Cancer Center at the Colorado State University (CSU) James L. Voss Veterinary Teaching Hospital. Daisy was the first canine patient anywhere to be treated with the SRT-100. The agreement with the school calls for the development of protocols for SRT use and the publishing of clinical data.
Daisy was diagnosed with two small mast cell tumors, one on her muzzle and the other on her lower eyelid. Following six treatments supported by SRT-100, there was a reduction in the size of both masses, negating the need for surgery, with hair loss being the only notable side effect.
“This was the first opportunity we had to employ the Sensus Healthcare device. In the past, we have been limited with our treatment options, especially when the tumors were too small or unreachable for traditional radiation therapies, as was the case with Daisy,” said Dr. Tiffany Martin, radiation oncologist at the Flint Animal Cancer Center. “We expect to see a growing use of this technology to treat other superficial skin or oral cancers, potentially alongside intraoperative surgery to treat questionable surgical margins.”
John Heinrich, Ph.D., a member of the Sensus Healthcare board of directors and the key relationship contact with CSU, added, “We are pleased to hear of Daisy’s recovery and of the groundbreaking work by the team of oncologists and veterinarians at Colorado State University Veterinary Teaching Hospital. Their work affirms the importance of our partnerships and how they continually expand our application potential and demonstrate the critical role of the SRT-100 in the treatment landscape.”
SRT-100 is used by dermatologists in human medicine to treat non-melanoma skin lesions, including basal cell and squamous cell carcinomas. The SRT-100 from Sensus Healthcare is being used to explore possible applications in veterinary medicine, which represents a potential new market for Sensus.
About Sensus Healthcare
Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for both oncological and non-oncological conditions. The Sculptura™ modulated robotic brachytherapy radiation oncology system provides targeted Directional Anisotropic Radiation Therapy (ART) and Brachytherapy utilizing our proprietary, state-of-the-art 3D Beam Sculpting™ to treat patients undergoing cancer treatment during surgery, or at the tumor site, fast and efficiently. Sensus also offers its proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is the culmination of more than a decade of research and development, to treat non-melanoma skin cancers and keloids with its SRT-100™, SRT-100+™ and SRT-100 Vision™ systems. With its portfolio of innovative medical device products, Sensus provides revolutionary treatment options to enhance the quality of life of patients around the world.
For more information, visit www.sensushealthcare.com.
Forward-Looking Statements
This press release includes statements that are, or may be deemed, ''forward-looking statements.'' In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," "approximately," "potential" or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words.
By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, and healthcare, regulatory and scientific developments and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward looking statements contained in this press release, as a result of, among other factors: our ability to achieve and sustain profitability; market acceptance of our product lines; our ability to successfully commercialize our products; our ability to compete effectively in selling our products and services, including responding to technological change and cost containment efforts of our customers; our need and ability to obtain additional financing in the future; our ability to expand, manage and maintain our direct sales and marketing organizations; our ability to obtain and maintain intellectual property of sufficient scope to adequately protect our products, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; the willingness of healthcare providers to purchase our products if coverage, reimbursement and pricing from third party payors for procedures using our products declines; the level and availability of government and third party payor reimbursement for clinical procedures using our products; our ability to effectively manage our anticipated growth, including hiring and retaining qualified personnel; the regulatory requirements applicable to us and our competitors; our ability to manufacture our products to meet demand; our current reliance on third party manufacturers and sole- or single-source suppliers, as well as our ability to successfully transition manufacturing of our products in-house; our ability to reduce the per unit manufacturing costs; our ability to efficiently manage our manufacturing processes; the regulatory and legal risks, and certain operating risks, that our international operations subject us to; the fact that product quality issues or product defects may harm our business; the accuracy of our financial statements and accounting estimates, including allowances for accounts receivable and inventory obsolescence; any product liability claims; new legislation, administrative rules, or executive orders, including those that impact taxes and international trade regulation; concentration of our customers in the U.S. and China, including the concentration of sales to one particular customer in the U.S.; and other risks described from time to time in Sensus Healthcare's filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.
In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this press release, they may not be predictive of results or developments in future periods. Any forward-looking statements that we make in this press release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this press release. You should read carefully our "Cautionary Note Regarding Forward-Looking Information" and the factors described in the "Risk Factors" section of our periodic reports filed with the Securities and Exchange Commission to better understand the risks and uncertainties inherent in our business.
Contact:
LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
kgolodetz@lhai.com
# # #
FAQ
What is the significance of the SRT-100 system in veterinary medicine?
What were the results of the first treatment using SRT-100 on a canine?
Who treated the first canine patient with the SRT-100 system?
What future developments are expected for SRT-100 in veterinary applications?
How does SRT-100 compare to traditional radiation therapies?
